Monday , December 18 2017
Home / Letter From The Editor / Editor’s Note, DCMS #166:

Editor’s Note, DCMS #166:

The FDA does not often reverse their decision on a medication but that has now happened with Avandia. With clinicians potentially using this TZD again, it’s a good time to revisit one of the most common errors from the past. The ISMP has had numerous reports of misinterpretations of the 8 mg strength. To find out what drug Avandia was often mistaken for, check out this week’s Disaster Averted.

In last week’s main newsletter we shared some protocols for self titration of insulin dosing in type 2 patients. However for our type 1 patients we need to get much more specific in dosing and our Clinical Text covers more complex insulin management for type 1 patients. Our Homerun Slides lend a plausible explanation as to why mortality increased in some studies when we tried to improve glucose levels, and our Mastery In Minutes video gives you some ways your patients can avoid mindless eating this holiday season.